BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 31323163)

  • 1. Surveillance factors change outcomes in patients with hepatocellular carcinoma due to chronic hepatitis C virus infection in New Zealand.
    Schauer C; van Rijnsoever M; Gane E
    J Viral Hepat; 2019 Dec; 26(12):1372-1376. PubMed ID: 31323163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increasing burden of advanced hepatocellular carcinoma in New Zealand-the need for better surveillance.
    Schauer C; Mules T; Rijnsoever MV; Gane E
    N Z Med J; 2020 May; 133(1515):25-34. PubMed ID: 32438374
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
    Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
    J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatocellular Carcinoma Surveillance in a Cohort of Chronic Hepatitis C Virus-Infected Patients with Cirrhosis.
    Abara WE; Spradling P; Zhong Y; Moorman A; Teshale EH; Rupp L; Gordon SC; Schmidt M; Boscarino JA; Daida YG; Holmberg SD;
    J Gastrointest Cancer; 2020 Jun; 51(2):461-468. PubMed ID: 31124041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada.
    Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M
    J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.
    van der Meer AJ; Feld JJ; Hofer H; Almasio PL; Calvaruso V; Fernández-Rodríguez CM; Aleman S; Ganne-Carrié N; D'Ambrosio R; Pol S; Trapero-Marugan M; Maan R; Moreno-Otero R; Mallet V; Hultcrantz R; Weiland O; Rutter K; Di Marco V; Alonso S; Bruno S; Colombo M; de Knegt RJ; Veldt BJ; Hansen BE; Janssen HLA
    J Hepatol; 2017 Mar; 66(3):485-493. PubMed ID: 27780714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States.
    Davila JA; Henderson L; Kramer JR; Kanwal F; Richardson PA; Duan Z; El-Serag HB
    Ann Intern Med; 2011 Jan; 154(2):85-93. PubMed ID: 21242365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diabetes Mellitus Heightens the Risk of Hepatocellular Carcinoma Except in Patients With Hepatitis C Cirrhosis.
    Yang JD; Mohamed HA; Cvinar JL; Gores GJ; Roberts LR; Kim WR
    Am J Gastroenterol; 2016 Nov; 111(11):1573-1580. PubMed ID: 27527741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidemiology and survival of hepatocellular carcinoma in the central region of Thailand.
    Somboon K; Siramolpiwat S; Vilaichone RK
    Asian Pac J Cancer Prev; 2014; 15(8):3567-70. PubMed ID: 24870758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients.
    Albeldawi M; Soliman M; Lopez R; Zein NN
    Dig Dis Sci; 2012 Dec; 57(12):3265-70. PubMed ID: 22695885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance.
    Huang CF; Yeh ML; Huang CI; Lin YJ; Tsai PC; Lin ZY; Chan SY; Chen SC; Yang HI; Huang JF; Lu SN; Dai CY; Jen CL; Yuan Y; L'Italien G; Wang LY; Lee MH; Yu ML; Chuang WL; Chen CJ
    Oncotarget; 2017 Jul; 8(27):43925-43933. PubMed ID: 28159934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Independent and additive interaction between tumor necrosis factor β +252 polymorphisms and chronic hepatitis B and C virus infection on risk and prognosis of hepatocellular carcinoma: a case-control study.
    Jeng JE; Wu HF; Tsai MF; Tsai HR; Chuang LY; Lin ZY; Hsieh MY; Chen SC; Chuang WL; Wang LY; Yu ML; Dai CY; Tsai JF
    Asian Pac J Cancer Prev; 2014; 15(23):10209-15. PubMed ID: 25556449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver fibrosis indices for identifying patients at low risk of developing hepatocellular carcinoma after eradication of HCV.
    Toyoda H; Tada T; Tachi Y; Hirai T; Yasuda S; Honda T; Hayashi K; Ishigami M; Goto H; Kumada T
    Antivir Ther; 2017; 22(3):185-193. PubMed ID: 27586087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Epidemiology of hepatocellular carcinoma in a rural area. Role of hepatotrophic viruses on survival].
    Rodríguez-Vidigal FF; Baz MJ; Romero J; del Puerto M
    An Med Interna; 2005 Apr; 22(4):162-6. PubMed ID: 16004511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence of hepatocellular carcinoma in patients with chronic liver disease due to hepatitis B or C and coinfected with the human immunodeficiency virus: A retrospective cohort study.
    Marcon PDS; Tovo CV; Kliemann DA; Fisch P; de Mattos AA
    World J Gastroenterol; 2018 Feb; 24(5):613-622. PubMed ID: 29434450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral hepatitis and hepatocellular carcinoma.
    Marrero CR; Marrero JA
    Arch Med Res; 2007 Aug; 38(6):612-20. PubMed ID: 17613352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors of survival in patients with non-resectable hepatocellular carcinoma: hepatitis C versus miscellaneous etiology.
    Abbas Z; Siddiqui AU; Luck NH; Hassan M; Mirza R; Naqvi A; Rizvi AH
    J Pak Med Assoc; 2008 Nov; 58(11):602-7. PubMed ID: 19024130
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration and cost-effectiveness of hepatocellular carcinoma surveillance in hepatitis C patients after viral eradication.
    Mueller PP; Chen Q; Ayer T; Nemutlu GS; Hajjar A; Bethea ED; Peters MLB; Lee BP; Janjua NZ; Kanwal F; Chhatwal J
    J Hepatol; 2022 Jul; 77(1):55-62. PubMed ID: 35157959
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.